Related Experiment Video

Updated: Aug 20, 2026

piggyBac Transposon System Modification of Primary Human T Cells
10:02

piggyBac Transposon System Modification of Primary Human T Cells

Published on: November 5, 2012

TG-4010 Transgene

Seth Cohen1, Howard L Kaufman

  • 1Department of Surgery, Columbia University, 177 Fort Washington Avenue, New York, NY 10032, USA.

Current Opinion in Investigational Drugs (London, England : 2000)
|January 15, 2005
PubMed

Insights

Transgene is developing TG-4010, a novel cancer immunotherapy. This modified vaccinia Ankara virus shows potential for treating non-small-cell lung, renal, and prostate cancers in ongoing Phase II trials.

Area of Science:

  • Oncology
  • Immunotherapy
  • Virology

Background:

  • Cancer immunotherapy aims to harness the immune system to fight tumors.
  • Modified vaccinia Ankara virus is a promising viral vector for vaccine development.
  • MUC1 and interleukin-2 are key targets and modulators in cancer immunity.

Purpose of the Study:

  • To evaluate TG-4010, a novel cancer immunotherapy.
  • To assess the potential of TG-4010 in treating various cancer types.
  • To advance TG-4010 through Phase II clinical trials.

Main Methods:

  • Development of TG-4010, a second-generation modified vaccinia virus Ankara.
  • Engineering the virus to encode MUC1 tumor antigen and interleukin-2.
  • Conducting Phase II clinical trials for specific cancer indications.

Main Results:

  • TG-4010 is under investigation as a potential cancer therapeutic.
  • Ongoing trials are evaluating its efficacy in non-small-cell lung cancer, metastatic renal cancer, and prostate cancer.
  • The study focuses on a novel approach combining viral vector technology with specific tumor antigens and immune stimulants.

Conclusions:

  • TG-4010 represents a novel immunotherapy candidate for diverse cancers.
  • Phase II trials are crucial for determining the clinical utility of TG-4010.
  • Further research will elucidate the full therapeutic potential of this oncolytic virus therapy.

More Related Videos

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness06:21

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness

Published on: May 7, 2018

Related Concept Videos

Transgenic Organisms00:53

Transgenic Organisms

Overview
Transgenic Organisms00:53

Transgenic Organisms

Overview
Transgenic Plants02:50

Transgenic Plants

Recombinant DNA technology called transgenesis is often used to add a foreign gene or remove a detrimental gene from an organism. Such genetically modified organisms are called transgenic organisms.
The first-ever transgenic plant was a tobacco plant developed in 1983 that showed resistance against the tobacco mosaic virus. Since then, many transgenic plants have been developed and commercialized for improving the agricultural, ornamental, and horticultural value of a crop plant. Transgenic...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...